Breaking News, Financial News

Leukogene Therapeutics Receives Funding for Cancer Therapies

South Carolina Research Authority provides funding that will help develop next-generation cancer therapies.

By: Rachel Klemovitch

Assistant Editor

Leukogene Therapeutics Inc., a biopharmaceutical company developing next-generation therapies for hematologic and other immunologically “cold” malignancies, announced that it has received funding from the South Carolina Research Authority (SCRA) and its investment affiliate, SC Launch Inc. “We are honored to receive this strategic funding from SCRA and SC Launch Inc. It will allow us to advance our programs toward the clinic, strengthen our position as a leader in developing next-generation c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters